Fintel reports that on December 11, 2024, Wells Fargo downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 1,360.58% Upside As of ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Q32 Bio (QTTB – Research Report), with a price target of ...

Fintel reports that on December 11, 2024, Leerink Partners downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Outperform to Market Perform. Analyst Price Forecast Suggests 260.75% Upside As of ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Q32 Bio (QTTB – Research Report) today and set a price target of $20.00.

Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares.

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

Key Insights Significant control over Q32 Bio by private equity firms implies that the general public has more power ...

Oppenheimer slashed its price target on the stock to $20 from $80, but maintained the stock at Outperform. This comes after ...

Equities researchers at BMO Capital Markets began coverage on shares of Q32 Bio (NASDAQ:QTTB – Get Free Report) in a research note issued on Friday, Marketbeat Ratings reports. The brokerage set an ...

Fintel reports that on December 6, 2024, BMO Capital initiated coverage of Q32 Bio (NasdaqGM:QTTB) with a Outperform recommendation. As of December 3, 2024, the average one-year price target for ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced topline results from the ...